Definition and Specifications of Prostaglandin D2 Receptor 2 - Pipeline Review, H1 2016
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor-Homologous Molecule Expressed On Th2 Cells or G-Protein Coupled Receptor 44 or CD294 or DP2 or PTGDR2) - Pipeline Review, H1 2016 is a new market research publication announced by Reportstack. This report provides in depth analysis on Prostaglandin D2 Receptor 2 (Chemoattractant Receptor-Homologous Molecule Expressed On Th2 Cells or G-Protein Coupled Receptor 44 or CD294 or DP2 or PTGDR2) targeted pipeline therapeutics.
To access full report with TOC, please visit Prostaglandin D2 Receptor 2 - Pipeline Review, H1 2016
The report provides comprehensive information on the Prostaglandin D2 Receptor 2 (Chemoattractant Receptor-Homologous Molecule Expressed On Th2 Cells or G-Protein Coupled Receptor 44 or CD294 or DP2 or PTGDR2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Prostaglandin D2 Receptor 2 (Chemoattractant Receptor-Homologous Molecule Expressed On Th2 Cells or G-Protein Coupled Receptor 44 or CD294 or DP2 or PTGDR2) targeted therapeutics development and features dormant and discontinued projects.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape for Prostaglandin D2 Receptor 2 (Chemoattractant Receptor-Homologous Molecule Expressed On Th2 Cells or G-Protein Coupled Receptor 44 or CD294 or DP2 or PTGDR2)
- The report reviews Prostaglandin D2 Receptor 2 (Chemoattractant Receptor-Homologous Molecule Expressed On Th2 Cells or G-Protein Coupled Receptor 44 or CD294 or DP2 or PTGDR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
Reasons to buy
- The report reviews Prostaglandin D2 Receptor 2 (Chemoattractant Receptor-Homologous Molecule Expressed On Th2 Cells or G-Protein Coupled Receptor 44 or CD294 or DP2 or PTGDR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
Reasons to buy
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Prostaglandin D2 Receptor 2 (Chemoattractant Receptor-Homologous Molecule Expressed On Th2 Cells or G-Protein Coupled Receptor 44 or CD294 or DP2 or PTGDR2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Devise corrective measures for pipeline projects by understanding Prostaglandin D2 Receptor 2 (Chemoattractant Receptor-Homologous Molecule Expressed On Th2 Cells or G-Protein Coupled Receptor 44 or CD294 or DP2 or PTGDR2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Companies Mentioned
Allergan Plc Brickell Biotech, Inc. Ligand Pharmaceuticals, Inc. Merck & Co., Inc. Novartis AG Oxagen Limited Panmira Pharmaceuticals, LLC. Pulmagen Therapeutics LLP Taisho Pharmaceutical Holdings Co., Ltd.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###
posted by Reportstack @ 23:26
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home